2axa › Citations

Structural basis for accommodation of nonsteroidal ligands in the androgen receptor.

Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT
J Biol Chem 280 37747-54 (2005)
Related entries: 2ax6, 2ax7, 2ax8, 2ax9

Cited: 102 times
EuropePMC logo PMID: 16129672

Abstract

The mechanism by which the androgen receptor (AR) distinguishes between agonist and antagonist ligands is poorly understood. AR antagonists are currently used to treat prostate cancer. However, mutations commonly develop in patients that convert these compounds to agonists. Recently, our laboratory discovered selective androgen receptor modulators, which structurally resemble the nonsteroidal AR antagonists bicalutamide and hydroxyflutamide but act as agonists for the androgen receptor in a tissue-selective manner. To investigate why subtle structural changes to both the ligand and the receptor (i.e. mutations) result in drastic changes in activity, we studied structure-activity relationships for nonsteroidal AR ligands through crystallography and site-directed mutagenesis, comparing bound conformations of R-bicalutamide, hydroxyflutamide, and two previously reported nonsteroidal androgens, S-1 and R-3. These studies provide the first crystallographic evidence of the mechanism by which nonsteroidal ligands interact with the wild type AR. We have shown that changes induced to the positions of Trp-741, Thr-877, and Met-895 allow for ligand accommodation within the AR binding pocket and that a water-mediated hydrogen bond to the backbone oxygen of Leu-873 and the ketone of hydroxyflutamide is present when bound to the T877A AR variant. Additionally, we demonstrated that R-bicalutamide stimulates transcriptional activation in AR harboring the M895T point mutation. As a whole, these studies provide critical new insight for receptor-based drug design of nonsteroidal AR agonists and antagonists.

Reviews - 2axa mentioned but not cited (2)

  1. Selective androgen receptor modulators in preclinical and clinical development. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Nucl Recept Signal 6 e010 (2008)
  2. PROTACs in the Management of Prostate Cancer. Yedla P, Babalghith AO, Andra VV, Syed R. Molecules 28 3698 (2023)

Articles - 2axa mentioned but not cited (19)

  1. Overcoming mutation-based resistance to antiandrogens with rational drug design. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. Elife 2 e00499 (2013)
  2. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. Askew EB, Gampe RT, Stanley TB, Faggart JL, Wilson EM. J Biol Chem 282 25801-25816 (2007)
  3. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. J Biol Chem 280 37747-37754 (2005)
  4. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT. J Biol Chem 282 13648-13655 (2007)
  5. Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets. Chen Z, Li HL, Zhang QJ, Bao XG, Yu KQ, Luo XM, Zhu WL, Jiang HL. Acta Pharmacol Sin 30 1694-1708 (2009)
  6. Mapping functional group free energy patterns at protein occluded sites: nuclear receptors and G-protein coupled receptors. Lakkaraju SK, Yu W, Raman EP, Hershfeld AV, Fang L, Deshpande DA, MacKerell AD. J Chem Inf Model 55 700-708 (2015)
  7. Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators. Bohl CE, Wu Z, Chen J, Mohler ML, Yang J, Hwang DJ, Mustafa S, Miller DD, Bell CE, Dalton JT. Bioorg Med Chem Lett 18 5567-5570 (2008)
  8. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. Xiang W, Zhao L, Han X, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Kirchhoff PD, Wang L, Matvekas A, He M, Wen B, Sun D, Wang S. J Med Chem 64 13487-13509 (2021)
  9. Endocrine Disruption at the Androgen Receptor: Employing Molecular Dynamics and Docking for Improved Virtual Screening and Toxicity Prediction. Wahl J, Smieško M. Int J Mol Sci 19 E1784 (2018)
  10. 1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment. Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G. J Med Chem 60 3082-3093 (2017)
  11. A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics. Wangtrakuldee P, Adeniji AO, Zang T, Duan L, Khatri B, Twenter BM, Estrada MA, Higgins TF, Winkler JD, Penning TM. J Steroid Biochem Mol Biol 192 105283 (2019)
  12. A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations. Liu HL, Zhong HY, Song TQ, Li JZ. Int J Mol Sci 18 E1823 (2017)
  13. Conformational dynamics of androgen receptors bound to agonists and antagonists. Gim HJ, Park J, Jung ME, Houk KN. Sci Rep 11 15887 (2021)
  14. Design, synthesis and evaluation of novel enzalutamide analogues as potential anticancer agents. Bhole RP, Chikhale RV, Wavhale RD, Asmary FA, Almutairi TM, Alhajri HM, Bonde CG. Heliyon 7 e06227 (2021)
  15. Development of β-amino-carbonyl compounds as androgen receptor antagonists. Zhang ZY, Zhu YH, Zhou CH, Liu Q, Lu HL, Ge YJ, Wang MW. Acta Pharmacol Sin 35 664-673 (2014)
  16. Computational Analysis of Residue-Specific Binding Free Energies of Androgen Receptor to Ligands. Shao G, Bao J, Pan X, He X, Qi Y, Zhang JZH. Front Mol Biosci 8 646524 (2021)
  17. An Assay on the Possible Effect of Essential Oil Constituents on Receptors Involved in Women's Hormonal Health and Reproductive System Diseases. Sakhteman A, Pasdaran A, Afifi M, Hamedi A. J Evid Based Integr Med 25 2515690X20932527 (2020)
  18. Design and synthesis of a new steroid-macrocyclic derivative with biological activity. López-Ramos M, Figueroa-Valverde L, Herrera-Meza S, Rosas-Nexticapa M, Díaz-Cedillo F, García-Cervera E, Pool-Gómez E, Cahuich-Carrillo R. J Chem Biol 10 69-84 (2017)
  19. ER/AR Multi-Conformational Docking Server: A Tool for Discovering and Studying Estrogen and Androgen Receptor Modulators. Wang F, Hu S, Ma DQ, Li Q, Li HC, Liang JY, Chang S, Kong R. Front Pharmacol 13 800885 (2022)


Reviews citing this publication (22)

  1. Protective actions of sex steroid hormones in Alzheimer's disease. Pike CJ, Carroll JC, Rosario ER, Barron AM. Front Neuroendocrinol 30 239-258 (2009)
  2. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Kolkhof P, Borden SA. Mol Cell Endocrinol 350 310-317 (2012)
  3. Mechanisms of Therapeutic Resistance in Prostate Cancer. Nakazawa M, Paller C, Kyprianou N. Curr Oncol Rep 19 13 (2017)
  4. Androgen receptor antagonists for prostate cancer therapy. Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, Claessens F. Endocr Relat Cancer 21 T105-18 (2014)
  5. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Gao W, Kim J, Dalton JT. Pharm Res 23 1641-1658 (2006)
  6. Bioinformatics and variability in drug response: a protein structural perspective. Lahti JL, Tang GW, Capriotti E, Liu T, Altman RB. J R Soc Interface 9 1409-1437 (2012)
  7. Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. Lallous N, Dalal K, Cherkasov A, Rennie PS. Int J Mol Sci 14 12496-12519 (2013)
  8. Update on Management of Cancer-Related Cachexia. Anderson LJ, Albrecht ED, Garcia JM. Curr Oncol Rep 19 3 (2017)
  9. Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase? Gao W, Dalton JT. Mol Interv 7 10-13 (2007)
  10. Androgen receptor as a therapeutic target. Gao W. Adv Drug Deliv Rev 62 1277-1284 (2010)
  11. Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance. Tian X, He Y, Zhou J. Front Pharmacol 6 57 (2015)
  12. A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. Maximov PY, Abderrahman B, Curpan RF, Hawsawi YM, Fan P, Jordan VC. Endocr Relat Cancer 25 R83-R113 (2018)
  13. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer. Mohler ML, Sikdar A, Ponnusamy S, Hwang DJ, He Y, Miller DD, Narayanan R. Int J Mol Sci 22 2124 (2021)
  14. Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery. Sakkiah S, Ng HW, Tong W, Hong H. Expert Opin Ther Targets 20 1267-1282 (2016)
  15. Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer. Asangani I, Blair IA, Van Duyne G, Hilser VJ, Moiseenkova-Bell V, Plymate S, Sprenger C, Wand AJ, Penning TM. J Biol Chem 296 100240 (2021)
  16. Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer. Narayanan R. Asian J Urol 7 271-283 (2020)
  17. Androgen and estrogen receptors: potential of crystallography in the fight against cancer. Nahoum V, Bourguet W. Int J Biochem Cell Biol 39 1280-1287 (2007)
  18. Androgen receptor modulators: a marriage of chemistry and biology. McEwan IJ. Future Med Chem 5 1109-1120 (2013)
  19. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance. Altschuler J, Stockert JA, Kyprianou N. Int J Mol Sci 22 2100 (2021)
  20. Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer. Ban F, Dalal K, LeBlanc E, Morin H, Rennie PS, Cherkasov A. Mol Inform 37 e1800043 (2018)
  21. The aldosterone receptor--new insights? Fuller P. Expert Opin Investig Drugs 15 201-203 (2006)
  22. Assessment of Prostate and Bladder Cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review. Bazarkin A, Morozov A, Androsov A, Fajkovic H, Rivas JG, Singla N, Koroleva S, Teoh JY, Zvyagin AV, Shariat SF, Somani B, Enikeev D. Curr Urol Rep 25 19-35 (2024)

Articles citing this publication (59)

  1. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS. Lancet Oncol 14 335-345 (2013)
  2. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R, Chinnaiyan A, Rubin MA, Pienta KJ, Robins DM. Cancer Res 69 4434-4442 (2009)
  3. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Pereira de Jésus-Tran K, Côté PL, Cantin L, Blanchet J, Labrie F, Breton R. Protein Sci 15 987-999 (2006)
  4. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, Chi KN, Gleave ME, Rennie PS, Collins CC, Cherkasov A. Genome Biol 17 10 (2016)
  5. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U, Pook E, Schäfer S, Rafestin-Oblin ME, Kolkhof P. J Biol Chem 285 29932-29940 (2010)
  6. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Clin Cancer Res 20 4075-4085 (2014)
  7. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, May LT, Christopoulos A, Dalton JT, Sexton PM, Zhang XK, Abagyan R. Proc Natl Acad Sci U S A 104 11927-11932 (2007)
  8. MicroRNAs are mediators of androgen action in prostate and muscle. Narayanan R, Jiang J, Gusev Y, Jones A, Kearbey JD, Miller DD, Schmittgen TD, Dalton JT. PLoS One 5 e13637 (2010)
  9. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Osguthorpe DJ, Hagler AT. Biochemistry 50 4105-4113 (2011)
  10. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens. Zhou J, Liu B, Geng G, Wu JH. Proteins 78 623-637 (2010)
  11. Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer. Bradbury RH, Hales NJ, Rabow AA, Walker GE, Acton DG, Andrews DM, Ballard P, Brooks NA, Colclough N, Girdwood A, Hancox UJ, Jones O, Jude D, Loddick SA, Mortlock AA. Bioorg Med Chem Lett 21 5442-5445 (2011)
  12. Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer. O'Mahony OA, Steinkamp MP, Albertelli MA, Brogley M, Rehman H, Robins DM. Mol Cancer Res 6 1691-1701 (2008)
  13. X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids. Lusher SJ, Raaijmakers HC, Vu-Pham D, Kazemier B, Bosch R, McGuire R, Azevedo R, Hamersma H, Dechering K, Oubrie A, van Duin M, de Vlieg J. J Biol Chem 287 20333-20343 (2012)
  14. Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring. Ohta K, Goto T, Fijii S, Suzuki T, Ohta S, Endo Y. Bioorg Med Chem 16 8022-8028 (2008)
  15. Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists. Salvati ME, Balog A, Shan W, Rampulla R, Giese S, Mitt T, Furch JA, Vite GD, Attar RM, Jure-Kunkel M, Geng J, Rizzo CA, Gottardis MM, Krystek SR, Gougoutas J, Galella MA, Obermeier M, Fura A, Chandrasena G. Bioorg Med Chem Lett 18 1910-1915 (2008)
  16. Molecular basis of agonicity and antagonicity in the androgen receptor studied by molecular dynamics simulations. Bisson WH, Abagyan R, Cavasotto CN. J Mol Graph Model 27 452-458 (2008)
  17. Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors. Petit-Topin I, Fay M, Resche-Rigon M, Ulmann A, Gainer E, Rafestin-Oblin ME, Fagart J. J Steroid Biochem Mol Biol 144 Pt B 427-435 (2014)
  18. Structure-based virtual screening and identification of a novel androgen receptor antagonist. Song CH, Yang SH, Park E, Cho SH, Gong EY, Khadka DB, Cho WJ, Lee K. J Biol Chem 287 30769-30780 (2012)
  19. A bioisosteric approach to the discovery of indole carbinol androgen receptor ligands. Lanter JC, Fiordeliso JJ, Allan GF, Musto A, Hahn do W, Sui Z. Bioorg Med Chem Lett 16 5646-5649 (2006)
  20. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations. Liu H, An X, Li S, Wang Y, Li J, Liu H. Mol Biosyst 11 3347-3354 (2015)
  21. Molecular Dynamics Studies on the Enzalutamide Resistance Mechanisms Induced by Androgen Receptor Mutations. Liu H, Wang L, Tian J, Li J, Liu H. J Cell Biochem 118 2792-2801 (2017)
  22. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. Vajda EG, López FJ, Rix P, Hill R, Chen Y, Lee KJ, O'Brien Z, Chang WY, Meglasson MD, Lee YH. J Pharmacol Exp Ther 328 663-670 (2009)
  23. Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. Narizhneva NV, Tararova ND, Ryabokon P, Shyshynova I, Prokvolit A, Komarov PG, Purmal AA, Gudkov AV, Gurova KV. Cell Cycle 8 4155-4167 (2009)
  24. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. Dalal K, Che M, Que NS, Sharma A, Yang R, Lallous N, Borgmann H, Ozistanbullu D, Tse R, Ban F, Li H, Tam KJ, Roshan-Moniri M, LeBlanc E, Gleave ME, Gewirth DT, Dehm SM, Cherkasov A, Rennie PS. Mol Cancer Ther 16 2281-2291 (2017)
  25. Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. Jayaraman A, Christensen A, Moser VA, Vest RS, Miller CP, Hattersley G, Pike CJ. Endocrinology 155 1398-1406 (2014)
  26. Fragment-based Shape Signatures: a new tool for virtual screening and drug discovery. Zauhar RJ, Gianti E, Welsh WJ. J Comput Aided Mol Des 27 1009-1036 (2013)
  27. Gartanin, an isoprenylated xanthone from the mangosteen fruit (Garcinia mangostana), is an androgen receptor degradation enhancer. Li G, Petiwala SM, Yan M, Won JH, Petukhov PA, Johnson JJ. Mol Nutr Food Res 60 1458-1469 (2016)
  28. Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients. Lallous N, Snow O, Sanchez C, Parra Nuñez AK, Sun B, Hussain A, Lee J, Morin H, Leblanc E, Gleave ME, Cherkasov A. Cancers (Basel) 13 2939 (2021)
  29. Muscle-bound? A tissue-selective nonsteroidal androgen receptor modulator. Wilson EM. Endocrinology 148 1-3 (2007)
  30. Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand 3-[76Br]bromo-hydroxyflutamide. Parent EE, Jenks C, Sharp T, Welch MJ, Katzenellenbogen JA. Nucl Med Biol 33 705-713 (2006)
  31. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant ARF876L nuclear import and function. Wu Z, Wang K, Yang Z, Pascal LE, Nelson JB, Takubo K, Wipf P, Wang Z. Prostate 80 319-328 (2020)
  32. Predictive Structure-Based Toxicology Approaches To Assess the Androgenic Potential of Chemicals. Trisciuzzi D, Alberga D, Mansouri K, Judson R, Novellino E, Mangiatordi GF, Nicolotti O. J Chem Inf Model 57 2874-2884 (2017)
  33. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells. Brooke GN, Gamble SC, Hough MA, Begum S, Dart DA, Odontiadis M, Powell SM, Fioretti FM, Bryan RA, Waxman J, Wait R, Bevan CL. Mol Cell Proteomics 14 1201-1216 (2015)
  34. Crystal structure, docking study and structure-activity relationship of carborane-containing androgen receptor antagonist 3-(12-hydroxymethyl-1,12-dicarba-closo-dodecaboran-1-yl)benzonitrile. Ohta K, Goto T, Fujii S, Kawahata M, Oda A, Ohta S, Yamaguchi K, Hirono S, Endo Y. Bioorg Med Chem 19 3540-3548 (2011)
  35. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. Singh P, Hallur G, Anchoori RK, Bakare O, Kageyama Y, Khan SR, Isaacs JT. Prostate 68 1570-1581 (2008)
  36. Carnosic acid promotes degradation of the androgen receptor and is regulated by the unfolded protein response pathway in vitro and in vivo. Petiwala SM, Li G, Bosland MC, Lantvit DD, Petukhov PA, Johnson JJ. Carcinogenesis 37 827-838 (2016)
  37. Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies. Snow O, Lallous N, Ester M, Cherkasov A. Int J Mol Sci 21 E5847 (2020)
  38. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway. Divakar S, Saravanan K, Karthikeyan P, Elancheran R, Kabilan S, Balasubramanian KK, Devi R, Kotoky J, Ramanathan M. Chem Biol Interact 275 22-34 (2017)
  39. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis. Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, Gulati R, Plymate S, Vessella RL, Corey E, Higano CS, Matsumoto AM, Montgomery RB, Nelson PS. PLoS One 9 e111545 (2014)
  40. Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents. Mochona B, Qi X, Euynni S, Sikazwi D, Mateeva N, Soliman KF. Bioorg Med Chem Lett 26 2847-2851 (2016)
  41. Perspectives on designs of antiandrogens for prostate cancer. Estébanez-Perpiñá E, Jouravel N, Fletterick RJ. Expert Opin Drug Discov 2 1341-1355 (2007)
  42. Apoptosis-mediated antiproliferation of A549 lung cancer cells mediated by Eugenia aquea leaf compound 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone and its molecular interaction with caspase receptor in molecular docking simulation. Hadisaputri YE, Cahyana N, Muchtaridi M, Lesmana R, Rusdiana T, Chaerunisa AY, Sufiawati I, Rostinawati T, Subarnas A. Oncol Lett 19 3551-3557 (2020)
  43. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor. Radaeva M, Ban F, Zhang F, LeBlanc E, Lallous N, Rennie PS, Gleave ME, Cherkasov A. Int J Mol Sci 22 2493 (2021)
  44. Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer. Yang J, Bohl CE, Nair VA, Mustafa SM, Hong SS, Miller DD, Dalton JT. J Pharmacol Exp Ther 317 402-408 (2006)
  45. Chiral dimethylamine flutamide derivatives--modeling, synthesis, androgen receptor affinities and carbon-11 labeling. Jacobson O, Laky D, Carlson KE, Elgavish S, Gozin M, Even-Sapir E, Leibovitc I, Gutman M, Chisin R, Katzenellenbogen JA, Mishani E. Nucl Med Biol 33 695-704 (2006)
  46. In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell. Cruz EC, Carecho AR, Saidel ME, Montanari CA, Leitão A. Bioorg Med Chem Lett 27 546-550 (2017)
  47. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. Liu B, Geng G, Lin R, Ren C, Wu JH. Chem Biol Drug Des 79 300-312 (2012)
  48. Specific interactions between androgen receptor and its ligand: ab initio molecular orbital calculations in water. Kobayashi I, Takeda R, Suzuki R, Shimamura K, Ishimura H, Kadoya R, Kawai K, Takimoto-Kamimura M, Kurita N. J Mol Graph Model 75 383-389 (2017)
  49. Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding Site. Liu Y, Wu M, Wang T, Xie Y, Cui X, He L, He Y, Li X, Liu M, Hu L, Cen S, Zhou J. Front Pharmacol 9 1419 (2018)
  50. Structural basis for computational screening of non-steroidal androgen receptor ligands. Nyrönen TH, Söderholm AA. Expert Opin Drug Discov 5 5-20 (2010)
  51. Lead evaluation of tetrahydroquinolines as nonsteroidal selective androgen receptor modulators for the treatment of osteoporosis. Nagata N, Furuya K, Oguro N, Nishiyama D, Kawai K, Yamamoto N, Ohyabu Y, Satsukawa M, Miyakawa M. ChemMedChem 9 197-206 (2014)
  52. Molecular Modeling Studies of Natural Inhibitors of Androgen Signaling in Prostate Cancer. Olubode SO, Bankole MO, Akinnusi PA, Adanlawo OS, Ojubola KI, Nwankwo DO, Edjebah OE, Adebesin AO, Ayodele AO. Cancer Inform 21 11769351221118556 (2022)
  53. Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors. Radaeva M, Li H, LeBlanc E, Dalal K, Ban F, Ciesielski F, Chow B, Morin H, Awrey S, Singh K, Rennie PS, Lallous N, Cherkasov A. Cells 11 2785 (2022)
  54. A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations. Doamekpor SK, Peng P, Xu R, Ma L, Tong Y, Tong L. Acta Crystallogr F Struct Biol Commun 79 95-104 (2023)
  55. Development and Evaluation of 99mTc Tricarbonyl Complexes Derived from Flutamide with Affinity for Androgen Receptor. Cardoso ME, Decuadra P, Zeni M, Delfino A, Tejería E, Coppe F, Mesa JM, Daher G, Giglio J, Carrau G, Gamenara D, Alonso O, Terán M, Rey A. Molecules 28 820 (2023)
  56. Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists. Wang L, Song T, Wang X, Li J. Front Pharmacol 9 864 (2018)
  57. Estrogens drive the endoplasmic reticulum-associated degradation and promote proto-oncogene c-Myc expression in prostate cancer cells by androgen receptor/estrogen receptor signaling. Erzurumlu Y, Dogan HK, Catakli D, Aydogdu E, Muhammed MT. J Cell Commun Signal 17 793-811 (2023)
  58. Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer. Thiyagarajan T, Ponnusamy S, Hwang DJ, He Y, Asemota S, Young KL, Johnson DL, Bocharova V, Zhou W, Jain AK, Petricoin EF, Yin Z, Pfeffer LM, Miller DD, Narayanan R. Proc Natl Acad Sci U S A 120 e2211832120 (2023)
  59. Novel Covalent Modifier-Induced Local Conformational Changes within the Intrinsically Disordered Region of the Androgen Receptor. Harnish MT, Lopez D, Morrison CT, Narayanan R, Fernandez EJ, Shen T. Biology (Basel) 12 1442 (2023)


Quick links